Panacea Biotec Limited
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- ₹129.1
- Today's High:
- ₹137.6
- Open Price:
- ₹136.4
- 52W Low:
- ₹107.15
- 52W High:
- ₹165
- Prev. Close:
- ₹135.05
- Volume:
- 51660
Company Statistics
- Market Cap.:
- ₹8.27 billion
- Book Value:
- 137.719
- Revenue TTM:
- ₹4.78 billion
- Operating Margin TTM:
- -4.49%
- Gross Profit TTM:
- ₹2.59 billion
- Profit Margin:
- 6.97%
- Return on Assets TTM:
- -3.5%
- Return on Equity TTM:
- -4%
Company Profile
Panacea Biotec Limited had its IPO on under the ticker symbol PANACEABIO.
The company operates in the Healthcare sector and Biotechnology industry. Panacea Biotec Limited has a staff strength of 0 employees.
Stock update
Shares of Panacea Biotec Limited opened at ₹136.4 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹129.1 - ₹137.6, and closed at ₹130.1.
This is a -3.67% slip from the previous day's closing price.
A total volume of 51,660 shares were traded at the close of the day’s session.
In the last one week, shares of Panacea Biotec Limited have slipped by -3.45%.
Panacea Biotec Limited's Key Ratios
Panacea Biotec Limited has a market cap of ₹8.27 billion, indicating a price to book ratio of 1.0376 and a price to sales ratio of 1.6432.
In the last 12-months Panacea Biotec Limited’s revenue was ₹4.78 billion with a gross profit of ₹2.59 billion and an EBITDA of ₹167.52 million. The EBITDA ratio measures Panacea Biotec Limited's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Panacea Biotec Limited’s operating margin was -4.49% while its return on assets stood at -3.5% with a return of equity of -4%.
In Q2, Panacea Biotec Limited’s quarterly earnings growth was a positive 0% while revenue growth was a positive 16.7%.
Panacea Biotec Limited’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 25.1115
- PEG
Its diluted EPS in the last 12-months stands at ₹5.38 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Panacea Biotec Limited’s profitability.
Panacea Biotec Limited stock is trading at a EV to sales ratio of 1.1097 and a EV to EBITDA ratio of 0.3418. Its price to sales ratio in the trailing 12-months stood at 1.6432.
Panacea Biotec Limited stock pays annual dividends of ₹0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- ₹12.71 billion
- Total Liabilities
- ₹3.32 billion
- Operating Cash Flow
- ₹0
- Capital Expenditure
- ₹0
- Dividend Payout Ratio
- 0%
Panacea Biotec Limited ended 2024 with ₹12.71 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹12.71 billion while shareholder equity stood at ₹8.44 billion.
Panacea Biotec Limited ended 2024 with ₹0 in deferred long-term liabilities, ₹3.32 billion in other current liabilities, in common stock, ₹0 in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹398.50 million and cash and short-term investments were ₹0. The company’s total short-term debt was ₹0 while long-term debt stood at ₹201.60 million.
Panacea Biotec Limited’s total current assets stands at ₹5.68 billion while long-term investments were ₹0 and short-term investments were ₹2.02 billion. Its net receivables were ₹600.90 million compared to accounts payable of ₹1.77 billion and inventory worth ₹2.02 billion.
In 2024, Panacea Biotec Limited's operating cash flow was ₹0 while its capital expenditure stood at ₹0.
Comparatively, Panacea Biotec Limited paid ₹0 in dividends in 2024.
Other key metrics
- Current Trading Price
- ₹130.1
- 52-Week High
- ₹165
- 52-Week Low
- ₹107.15
- Analyst Target Price
- ₹
Panacea Biotec Limited stock is currently trading at ₹130.1 per share. It touched a 52-week high of ₹165 and a 52-week low of ₹165. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹131.33 and 200-day moving average was ₹127.77 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 8136.1% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About Panacea Biotec Limited
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Panacea Biotec Limited, a biotechnology company, engages in the research and development, manufacture, and marketing of pharmaceutical formulations and vaccines in India. It operates through Vaccines and Formulations segments. The company’s product portfolio includes prescription products in various therapeutic areas, such as pain management, diabetes and cardiovascular management, oncology, renal disease management, osteoporosis management, anti-tubercular, and gastro-intestinal care; and pneumococcal vaccine, dengue tetravalent vaccine, typhoid conjugate vaccine, and universal flu vaccine. It also exports its products to approximately 30 countries, including the United States, Germany, the Russian Federation, Brazil, Turkey, Bosnia, Tanzania, Kenya, Serbia, Vietnam, Sri Lanka, the Philippines, Panama, Ecuador, Trinidad and Tobago, etc. The company has a collaboration agreement with the Russian Direct Investment Fund for producing Covid-19 vaccine, Sputnik-V; and the Coalition for Epidemic Preparedness Innovations and Translational Health Science and Technology Institute to develop vaccine candidates that could protect against SARS-Cov-2 variants and other Beta coronaviruses. Panacea Biotec Limited was incorporated in 1984 and is based in New Delhi, India.